Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GLS-012 by Guangzhou Gloria Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
GLS-012 is under clinical development by Guangzhou Gloria Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According...